Baseline clinical data
| . | All . | Pure LCDD . | LCDD+CN . | HCDD . | LHCDD . |
|---|---|---|---|---|---|
| (n = 255) . | (n = 154) . | (n = 58) . | (n = 23) . | (n = 20) . | |
| Age, y | 64 (53-75) | 63 (55-73) | 67 (57-75) | 59 (55-73) | 57 (49-72) |
| Men/women | 133/122 | 80/74 | 29/29 | 12/11 | 12/8 |
| Hematological data | |||||
| MGRS, n (%) | 163 (64) | 126 (82) | 0* | 22 (96) | 19 (95) |
| Symptomatic MM, n (%) | 86 (34) | 28 (18.2) | 58 (100%)* | 1 (4)† | 1 (5)† |
| WM, n (%) | 3 (1) | 3 (2) | 0 | 0 | 0 |
| CLL, n (%) | 1 (0.4) | 1 (0.6) | 0 | 0 | 0 |
| B-cell lymphoma, n (%) | 2 (0.8) | 2 (1.3) | 0 | 0 | 0 |
| dFLC | 431 (74-2318) | 1478 (246-4271) | 5405 (2567-15 012)* | 140 (69-458) | 602 (123-1177) |
| κ FLC excess, n (%) | 113/139 (81.3) | 69/84 (82.1) | 22/27 (81.5) | 11/16 (68.8) | 11/12 (91.7) |
| λ FLC excess, n (%) | 26/139 (18.7) | 15/84 (17.9) | 5/27 (18.5) | 5/16 (31.2) | 1/12 (8.3) |
| Renal manifestations | |||||
| Serum creatinine, μmol/L§ | 269 (169-471) | 247 (169-441) | 494 (300-804)* | 144 (133-167) | 228 (144-400) |
| eGFR (mL/min/1.73 m2) | 24.3 (11.9-42.9) | 21 (11-32) | N/A | 37 (32-40)† | 27 (15-41) |
| CKD ≥4, n (%) | 115 (45) | 99 (64.2) | 0 (0) | 6 (26) | 10 (50) |
| AKI, n (%) | 58 (23) | 0 | 58 (100)* | 0 | 0 |
| Hemodialysis at diagnosis, n (%) | 60 (23) | 3 (3) | 52 (90)* | 1 (4) | 2 (10) |
| 24-h proteinuria, g§ | 1.8 (0.8-4) | 2.4 (1.2-4.5) | 2 (1.2-4.0) | 3.6 (2-5)‡ | 2.9 (1.3-5.2) |
| Serum albumin, g/L§ | 33 (29-40) | 33 (29-40) | 35 (30-40) | 26 (24-30)‡ | 30 (29-37) |
| Nephrotic syndrome, n (%) | 56 (22) | 35 (29) | 0 (0)* | 14 (61)‡ | 7 (35) |
| Hematuria, n (%) | 147 (58) | 70 (59) | 29 (50) | 19 (83)‡ | 15 (75) |
| Hypertension, n (%) | 140 (55) | 61 (51) | 35 (60) | 17 (74)‡ | 11 (55) |
| Extrarenal manifestations | |||||
| ≥1 site/organ involved, n (%) | 89 (35) | 75 (48.7)‖ | 6 (10.3) | 6 (26.1) | 2 (10) |
| Liver, n (%) | 43 (17) | 34 (22)‖ | 4 (7) | 3 (13) | 2 (10) |
| Heart, n (%) | 31 (12) | 27 (18)‖ | 1 (2) | 2 (9) | 1 (5) |
| Peripheral nerve, n (%) | 24 (9) | 20 (13) | 4 (7) | 0 | 0 |
| Minor salivary gland, n (%) | 17 (7) | 14 (9) | 1 (2) | 2 (9) | 0 |
| Gastrointestinal tract, n (%) | 11 (4) | 9 (6) | 0 | 2 (9) | 0 |
| Skin, n (%) | 9 (4) | 8 (5) | 0 | 0 | 1 (5) |
| Cutis laxa. n (%) | 3 (1) | 0 | 0 | 3 (13) | 0 |
| Other | 6 (2) | 6 (4) | 0 | 0 | 0 |
| Lung, n (%) | 6 (2) | 6 (4) | 0 | 0 | 0 |
| Bone marrow, n (%) | 2 (1) | 2 (1) | 0 | 0 | 0 |
| Abdominal fat, n (%) | 2 (1) | 2 (1) | 0 | 0 | 0 |
| Lymph node, n (%) | 2 (1) | 2 (1) | 0 | 0 | 0 |
| Thyroid, n (%) | 1 (0.4) | 0 | 0 | 1 (4) | 0 |
| Vocal cords, n (%) | 1 (0.4) | 1 (1) | 0 | 0 | 0 |
| . | All . | Pure LCDD . | LCDD+CN . | HCDD . | LHCDD . |
|---|---|---|---|---|---|
| (n = 255) . | (n = 154) . | (n = 58) . | (n = 23) . | (n = 20) . | |
| Age, y | 64 (53-75) | 63 (55-73) | 67 (57-75) | 59 (55-73) | 57 (49-72) |
| Men/women | 133/122 | 80/74 | 29/29 | 12/11 | 12/8 |
| Hematological data | |||||
| MGRS, n (%) | 163 (64) | 126 (82) | 0* | 22 (96) | 19 (95) |
| Symptomatic MM, n (%) | 86 (34) | 28 (18.2) | 58 (100%)* | 1 (4)† | 1 (5)† |
| WM, n (%) | 3 (1) | 3 (2) | 0 | 0 | 0 |
| CLL, n (%) | 1 (0.4) | 1 (0.6) | 0 | 0 | 0 |
| B-cell lymphoma, n (%) | 2 (0.8) | 2 (1.3) | 0 | 0 | 0 |
| dFLC | 431 (74-2318) | 1478 (246-4271) | 5405 (2567-15 012)* | 140 (69-458) | 602 (123-1177) |
| κ FLC excess, n (%) | 113/139 (81.3) | 69/84 (82.1) | 22/27 (81.5) | 11/16 (68.8) | 11/12 (91.7) |
| λ FLC excess, n (%) | 26/139 (18.7) | 15/84 (17.9) | 5/27 (18.5) | 5/16 (31.2) | 1/12 (8.3) |
| Renal manifestations | |||||
| Serum creatinine, μmol/L§ | 269 (169-471) | 247 (169-441) | 494 (300-804)* | 144 (133-167) | 228 (144-400) |
| eGFR (mL/min/1.73 m2) | 24.3 (11.9-42.9) | 21 (11-32) | N/A | 37 (32-40)† | 27 (15-41) |
| CKD ≥4, n (%) | 115 (45) | 99 (64.2) | 0 (0) | 6 (26) | 10 (50) |
| AKI, n (%) | 58 (23) | 0 | 58 (100)* | 0 | 0 |
| Hemodialysis at diagnosis, n (%) | 60 (23) | 3 (3) | 52 (90)* | 1 (4) | 2 (10) |
| 24-h proteinuria, g§ | 1.8 (0.8-4) | 2.4 (1.2-4.5) | 2 (1.2-4.0) | 3.6 (2-5)‡ | 2.9 (1.3-5.2) |
| Serum albumin, g/L§ | 33 (29-40) | 33 (29-40) | 35 (30-40) | 26 (24-30)‡ | 30 (29-37) |
| Nephrotic syndrome, n (%) | 56 (22) | 35 (29) | 0 (0)* | 14 (61)‡ | 7 (35) |
| Hematuria, n (%) | 147 (58) | 70 (59) | 29 (50) | 19 (83)‡ | 15 (75) |
| Hypertension, n (%) | 140 (55) | 61 (51) | 35 (60) | 17 (74)‡ | 11 (55) |
| Extrarenal manifestations | |||||
| ≥1 site/organ involved, n (%) | 89 (35) | 75 (48.7)‖ | 6 (10.3) | 6 (26.1) | 2 (10) |
| Liver, n (%) | 43 (17) | 34 (22)‖ | 4 (7) | 3 (13) | 2 (10) |
| Heart, n (%) | 31 (12) | 27 (18)‖ | 1 (2) | 2 (9) | 1 (5) |
| Peripheral nerve, n (%) | 24 (9) | 20 (13) | 4 (7) | 0 | 0 |
| Minor salivary gland, n (%) | 17 (7) | 14 (9) | 1 (2) | 2 (9) | 0 |
| Gastrointestinal tract, n (%) | 11 (4) | 9 (6) | 0 | 2 (9) | 0 |
| Skin, n (%) | 9 (4) | 8 (5) | 0 | 0 | 1 (5) |
| Cutis laxa. n (%) | 3 (1) | 0 | 0 | 3 (13) | 0 |
| Other | 6 (2) | 6 (4) | 0 | 0 | 0 |
| Lung, n (%) | 6 (2) | 6 (4) | 0 | 0 | 0 |
| Bone marrow, n (%) | 2 (1) | 2 (1) | 0 | 0 | 0 |
| Abdominal fat, n (%) | 2 (1) | 2 (1) | 0 | 0 | 0 |
| Lymph node, n (%) | 2 (1) | 2 (1) | 0 | 0 | 0 |
| Thyroid, n (%) | 1 (0.4) | 0 | 0 | 1 (4) | 0 |
| Vocal cords, n (%) | 1 (0.4) | 1 (1) | 0 | 0 | 0 |
CKD, chronic kidney disease; CLL, chronic lymphocytic leukemia; WM, Waldenström macroglobulinemia.
P < .05, comparison between LCDD+CN and pure LCDD, HCDD, and LHCDD.
P < .05, comparison between HCDD and pure LCDD.
P < .05, comparison between LHCDD and pure LCDD.
Results are expressed as median (IQR).
P < .05, comparison between LCDD and LCDD+CN, HCDD and LHCDD.